TAMSULOSIN TREATMENT OF 19365 PATIENTS WITH LOWER URINARY
TRACT SYMPTOMS: DOES CO-MORBIDITY ALTER TOLERABILITY?
Article published in Urologia Polska 1999/52/2.
authors
-
Martin C. Michel, Ludwig Mehlburger, Hans-Uirich Bressel, Helmut Schumacher, Rafael F. Schaffers, Mark Goepel
- From the Departments of Medicine and Urology, University of Essen,
Boehringer Ingelheim, Ingelheim and Yamanouchi Pharma, Heidelberg
keywords
-
prostate BPH urinary tract concomitant disease
summary
- Purpose. We compare the tolerability and blood pressure effects of 0.4 mg. tamsulosin
- once daily in patients with lower urinary symptoms suggestive of benign prostatic obstruction
- with or without concomitant disease and/or antihypertensive medication.
- Materials and methods: Data from 2 open label, observational studies (study 1,9507 patients
- treated for 4 weeks and study 2, 9858 patients treated for 12 weeks) were analysed for
- global tolerability and effects on blood pressure stratifying for co-morbidity (none, diabetes,
- hypertension, other cardiovascular disease) and co-medication (diuretics, beta-blockers,
- calcium channel blockers, angiotensin converting enzyme inhibitors).
- Results. Overall 90 and 95% of patients in studies 1 and 2, respectively, reported good or
- very good tolerability. While global tolerability was slightly reduced in patients with
- concomitant disease or some forms of medication (p <0.05), it was rated as good or very
- good by more than 90 and 95% of patients even in those groups. In control patients, that is
- those with neither co-morbidity nor co-medication, the tamsulosin induced blood pressure
- reductions were similar to those previously reported for placebo treatment but were
- statistically significant (p <0.05). Mean additional blood pressure reductions in patients
- with concomitant disease or medication were not more than 2 mm Hg.
- Conclusions. Tamsulosin is well tolerated and has marginal effects on blood pressure in the
- majority ofpatients. It largely maintains its good global tolerability and minimal blood
- pressure effects in patients with cardiovascular co-morbidity or diabetes, or those on co-
- medication with antihypertensive agents.
references
- [1] Khoury, A. F. and Kaplan, N. M.: Alpha-blocker therapy of hypertension. An
- unfulfilledpromise. J.A.M.A., 266: 394,1991.
- [2] van Zwieten, P. A.: a-Adrenoceptor blocking agents in the treatment of
- hypertension. In: Hypertension: Pathophysiology, Diagnosis and Management,
- 2nd ed. Edited by J. H. Laragh and B. M. Brenner, New York: Raven Press,
- chapt.175, pp. 2917- 2935,1995.
- [3] Oesterling, J. E.: Benign.prostatic hyperplasia. Medical and minimally invasive
- treatment options. New Engl. J. Med., 332: 99,199fi.
- [4] Eri, L. M. and Tveter, K. J.: a-Blockade in the treatment of Symptomatic benign
- prostatic hyperplasia. J. Urol., 154: 923,1995.
- [5] Gee, W. R, Holtgrewe, H. L., Albertsen, P. C, Litwin, M. S., Manyak,
- M. J., 0'Leary, M. P. and Painter, M. R.: Practice trends in the diagnosis and
- management of benign prostatic hyperplasia in the United States. J. Urol., 164:205,
- 1995.
- [6] Carruther¶, S. G.: Adverse effects of al-adrenergic blocking drugs. DrugSafety,
- 11:12,1994.
- [7] Kirby, R. S.: Doxazosin in benign prostatic hyperplasia: effects on blood pressure
- and urinary flow in normotensive and hypertensive men. Urology, 46:182,1995.
- [8] Lukacs, B., Leplege, A., Thibault, P. and Jardin, A.: Prospective study of men
- with clinical benign prostatic hyperplasia treated with alfuzosin by general
- practitioners: 1-year results. Urology, 48: 731,1996.
- [9] Michel, M. C, Grubbel, B., Taguchi, K., Verfiirth, R, Otto, T. and
- Krópfl, D.: Drugs for treatment ofbenign prostatic hyperplasia: affinity Comparison
- at cloned al-adrenoceptor subtypes and in human prostate. J. Auton. Pharmacol.,
- 16: 21,1996.
- [10] Wilde, M. I. and McTavish, D.: Tamsulosin. A reuiew of its pharmacological
- properties and therapeutic potential in the management of benign prostatic
- hyperplasia. Drugs, 52: 883,1996.
- [U] Taguchi, K., Schafers, R. F. and Michel, M. C: Radioreceptor assay analysis
- of tamsulosin and terazosin pharmacokinetics. Brit. J. Clin. Pharmacol., 45: 49,
- 1998.
- [12] Chapple, C. R., Wyndaele, J. J., Nordling, J., Boeminghaus, F., Ypma,
- A. F. G. V. M., Abrams, P. and the European Tamsulosin Study Group:
- Tamsulosin, the first prostate-selective al A-adrenoceptor antagonist. A meta-analysis
- of two randomized, placebo-controlled multicentre studies in patients with benign
- prostatic obstruction (Symptomatic BPH). Eur. Urol., 29:155,1996.
- [13] Lepor, H.: Phase III multicenter, placebo-controlled study of tamsulosin in benign
- prostatic hyperplasia. Urology, 51: 892,1998.
- [14] Cockett, A. T. K., Khoury, S., Aso, Y., Chatelain, C, Denis, L., Griffiths,
- L. and Murphy, G.: The 2nd International Consultation on Benign Prostatic
- Hyperplasia. Channel Island: Scientific Communication International Ltd., pp.
- 624-631,1994.
- [15] Motulsky, H. ]., Snavely, M. D., Hughes, R. J. andlnsel, P. A.:Interaction
- of verapamil and other calcium channel Uockers with al- and al-adrenergic receptors.
- Circ. Res., 52: 226,1983.
- [16] Andersson, K. E., Lepor, H. and Wyllie, M. G.: Prostatic al-adrenoceptors
- and uroselectwity. Prostate, 30: 202,1997.
- [17] Chapple, C. R.: Selective al-adrenoceptor antagonists in benign prostatic
- hyperplasia: rationale and clinical experience. Eur. Urol., 29:129,1996.
- [18] Buzelin, J. M., Fonteyne, E., Kontturi, M. J., Witjes, W. P. J., Khan, A.
- and the European Tamsulosin Study Group: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (Symptomatic benign prostatic hyperplasia).Brit.J.Urol., 80: 597,1997.
- [19] Lee, E. and Lee, C: Clinical Comparison of selective and non-selective al A-
- adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a
- fixed dose and terazosin in increasing doses. Brit. J. Urol., 80: 606,1997.
- [20] Chapple, C. R., Carter, P., Christmas, T. ]., Kirby, R. S., Bryan, }.,
- Milroy, E. J. and Abrams, P.: A three month double-blind study of doxazosin as
- treatment for benign prostatic bladder outlet obstruction. Brit. J. Urol., 74:50,1994.
- [21] Roehrborn, C. G. and Siegel, R. L.: Safety and effcacy of doxazosin in benign
- prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled
- studies. Urology, 48: 406,1996.
- [22] Roehrborn, C. G., Oesterling, J. E., Auerbach, S? Kaplan, S. A., Lloyd,
- L. K., Milam, D. E. and Padley, R. J.: The Hytrin community assessment trial
- study: a one-year study of terazosin versus placebo in the treatment of patients with
- symptomatic benign prostatic hyperplasia (BPH). Urology, 47:159,1996.
- [23] Brawer, M. K., Adams, G., Epstein, H. and the Terazosin Benign Prostatic
- Hyperplasia Study Group: Terazosin in the treatment of benign prostatic
- hyperplasia. Arch. Fam. Med., 2: 929,1993.
- [24] Lepor, H., Williford, W. O., Barry, M. ]., Brawer, M. K., Dixon, C. M.,
- Gormley, G., Haakenson, C, Machi, M., Narayan, R, Padley, R. J. and
- the Veterans Affairs Cooperative Benign Prostatic Hyperplasia Study Group:
- The efficacy of terazosin, Gnasteride or both in benign prostatic hyperplasia. New
- Engl. J. Med., 335: 533,1996.
- [25] Jardin A., Bensadoun, H., Delauche-Cavallier, M. C, Attali, P. and
- The BPH-ALF Group: Alfuzosinfor treatment of benign prostatic hypertrophy.
- Lancet, 337:1457,1991.
- [26] Buzelin, J. M., Delauche-Cavallier, M. C, Roth, S., Geffriaud-
- Ricouard, C. and Santoni, J. R: Clinical uroselectivity: evidencefrom patients
- treated with slowrelease alfuzosinfor Symptomatic benign prostatic obstruction. Brit.
- J. Urol., 79: 898,1997.
- [27] Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, }., Gaffney, M.,
- Ice, K., Dias, N. for the Multicenter Study Group: Doxazosin for the treatment
- of benign prostatic hyperplasia in patients with mild to moderate essential
- hypertension: a double- blind, placebo-controlled, dose-response multicenter study.
- J. Urol., 154:110,1995.
- [28] Fawzy, A., Braun, K., Lewis, G. R, Gaffney, M., Ice, K., Dias, N. for the
- Multicenter Study Group: Doxazosin in the treatment of benign prostatic
- hyperplasia in normotensive patients: a multicenter study. J. Urol., 154:105,1995.
- [29] de Plan±ue, B. A.: A double-blind comparatwe study ofdoxazosin and prazosin
- when administered with b-blockers or diuretics. Amer. Heart J., 121: 304,1991.
- [30] Englert, R. G. and Barlage, U.: The addition of doxazosin to the treatment
- regimen of patients with hypertension not adequately controlled by b-blockers. Amer.
- Heart J., 121:311,1991.
- [31] Lindner, U. K., von Manteuffel, G. E. and Stafunsky, M.: The addition of
- doxazosin to the treatment regimen of hypertensive patients not responswe to
- nifedipine. Amer. Heart}., 116:1814,1988.
- [32] Englert, R. G. and Mauersberger, H.: A single-blind study of doxazosin in
- the treatment of essential hypertension when added to nonresponders to angiotensin-
- converting enzyme inhibitor therapy. Amer. Heart ]., 116:1826,1988.
|